Roivant Sciences Ltd (ROIV) Stock Price, Quote & News

Company Profile

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythemat...

Industry: Biotechnology

Sector: Healthcare

Website: roivant.com

Address:

11-12 St. James's Square, Suite 1 3rd Floor, London, United Kingdom

Digger75 Oct. 23 at 2:51 PM

$ROIV this is going much higher

0 · Reply

DocPharm Oct. 23 at 1:37 PM

$ROIV

0 · Reply

DocPharm Oct. 22 at 8:28 PM

$MRNA down she blows May have to pay a big chunk to $ABUS / $ROIV / Genevant soon, too

2 · Reply

MyBrokenBus Oct. 22 at 4:13 PM

$ROIV Again. Roivant cares not for surrounding market volatility.

0 · Reply

lakeswim951 Oct. 21 at 3:30 PM

$ROIV The price action here along with $ABUS and $IMVT has been amazing👌

0 · Reply

DocPharm Oct. 21 at 12:04 PM

$INTC 😎😎 still has much more to go IMO, but nearing a double for moi Trimming 10-20% and rotating into bios $ABUS $EDIT $ROIV barinthus/vaccitech

2 · Reply

DocPharm Oct. 20 at 2:05 PM

$ROIV keep on keepin on

1 · Reply

Alfalcon Oct. 19 at 12:29 AM

$ROIV

0 · Reply

bbbloo Oct. 17 at 12:23 AM

$ROIV I like that this stock was up on a generally down day and that it has continued to rise in ah. Not sure what is happening but quietly and without any buzz this stock is steadily rising little bit by little bit.

2 · Reply

MTGDW Oct. 16 at 3:57 PM

$ROIV anyone concerned by Venker’s constant selling?

3 · Reply

Roivant Sciences Ltd. (ROIV) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 24, 2025, 10:57 PM EDT - 4 weeks ago

Roivant Sciences Ltd. (ROIV) Presents at Bank of America Global Healthcare Conference 2025 Transcript

Sep 23, 2025, 5:45 AM EDT - 4 weeks ago

Roivant Sciences Ltd. (ROIV) Q1 2024 Earnings Call Transcript

Sep 17, 2025, 3:43 PM EDT - 5 weeks ago

Roivant Sciences Ltd. - Special Call

Sep 17, 2025, 12:13 PM EDT - 5 weeks ago

Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial

Sep 17, 2025, 8:21 AM EDT - 5 weeks ago

Roivant, Priovant Therapeutics' rare skin and muscle disease drug shows promise in trial

Sep 17, 2025, 7:00 AM EDT - 5 weeks ago

Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)

Sep 11, 2025, 4:30 PM EDT - 6 weeks ago

Roivant Named on Fortune Media and Great Place To Work's 2025 Best Workplaces in BioPharma List

Sep 8, 2025, 8:25 PM EDT - 6 weeks ago

Roivant Sciences Ltd. (ROIV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 7:00 AM EDT - 7 weeks ago

Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

Sep 3, 2025, 11:07 PM EDT - 7 weeks ago

Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data Transcript

Sep 3, 2025, 1:01 PM EDT - 7 weeks ago

Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients

Aug 15, 2025, 9:30 AM EDT - 2 months ago

Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack

Aug 11, 2025, 12:28 PM EDT - 2 months ago

Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript

Aug 11, 2025, 7:00 AM EDT - 2 months ago

Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update

Jul 28, 2025, 4:05 PM EDT - 3 months ago

Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025

Jun 16, 2025, 7:00 AM EDT - 4 months ago

Pulmovant Announces Publication of Pharmacokinetics and Lung Deposition Data for Inhaled Mosliciguat in Clinical Pharmacokinetics

Jun 9, 2025, 4:05 PM EDT - 4 months ago

Roivant and Priovant to Host Investor Video Conference at 1:00 PM ET on Tuesday, June 17 on Brepocitinib and the Unmet Medical Need in Dermatomyositis

May 29, 2025, 2:17 PM EDT - 5 months ago

Roivant Sciences Ltd. (ROIV) Q4 2024 Earnings Call Transcript

May 29, 2025, 7:00 AM EDT - 5 months ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025, and Provides Business Update

May 15, 2025, 4:10 PM EDT - 5 months ago

Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2025 and Provide Business Update on Thursday, May 29, 2025

Apr 23, 2025, 12:13 PM EDT - 6 months ago

Roivant Sciences: Primed For Growth With A De-Risked Pipeline

Apr 21, 2025, 7:00 AM EDT - 6 months ago

Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren's Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1402

Mar 19, 2025, 7:45 AM EDT - 7 months ago

Roivant Announces Positive Results for Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Studies

Mar 18, 2025, 4:32 PM EDT - 7 months ago

Roivant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs

Mar 3, 2025, 9:15 AM EST - 8 months ago

Genevant Sciences and Arbutus Biopharma Initiate International Patent Infringement Enforcement Actions Against Moderna

ABUS

Feb 10, 2025, 12:32 PM EST - 9 months ago

Roivant Sciences Ltd. (ROIV) Q3 2024 Earnings Call Transcript

Feb 10, 2025, 7:00 AM EST - 9 months ago

Roivant Reports Financial Results for the Third Quarter Ended December 31, 2024, and Provides Business Update

Feb 5, 2025, 12:12 PM EST - 9 months ago

Roivant: Telavant-Like Success Will Be Challenging To Replicate (Rating Downgrade)

Feb 3, 2025, 7:00 AM EST - 9 months ago

Zest Health Announces $13M in Funding to Curb Unnecessary Pharmaceutical Spend through High-Touch Care

Jan 29, 2025, 4:05 PM EST - 9 months ago

Roivant to Report Financial Results for the Third Quarter Ended December 31, 2024 and Provide Business Update on Monday, February 10, 2025

Jan 13, 2025, 9:00 AM EST - 10 months ago

Scipher Medicine and Roivant Partner to Bring Precision Medicine Insights to Rheumatology Drug Discovery and Development

Dec 4, 2024, 8:30 AM EST - 11 months ago

Roivant Sciences: A Biotech Growth Play With Major Ambitions

Dec 3, 2024, 7:19 AM EST - 11 months ago

Roivant's lung disease drug fails mid-stage trial

Nov 12, 2024, 2:41 PM EST - 1 year ago

Roivant Sciences Ltd. (ROIV) Q2 2024 Earnings Call Transcript

Oct 29, 2024, 4:35 PM EDT - 1 year ago

Roivant to Report Financial Results for the Second Quarter Ended September 30, 2024 and Provide Business Update on Tuesday, November 12, 2024

Oct 22, 2024, 12:31 PM EDT - 1 year ago

Roivant Sciences: Good Value, But Near-Term Catalysts Could Bring Volatility

Sep 18, 2024, 3:20 PM EDT - 1 year ago

Roivant Sciences Offloads Psoriasis Medicine Maker To Organon For Up To $1.2B

OGN

Sep 18, 2024, 10:59 AM EDT - 1 year ago

Roivant Flips a Skin Drug to Organon

OGN

Sep 18, 2024, 7:30 AM EDT - 1 year ago

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

OGN

Sep 10, 2024, 6:30 AM EDT - 1 year ago

Roivant Unveils New Pipeline Program Mosliciguat, A Potential First-In-Class and Best-In-Category Inhaled Once-Daily Soluble Guanylate Cyclase (sGC) Activator

Sep 10, 2024, 6:30 AM EDT - 1 year ago

Pulmovant presents positive proof-of-concept data from the Phase 1b ATMOS study of Mosliciguat in Pulmonary Hypertension at European Respiratory Society Congress

Sep 9, 2024, 12:54 PM EDT - 1 year ago

What's Going In With Vivek Ramaswamy-Founded Roivant Sciences Stock On Monday?

Sep 9, 2024, 7:00 AM EDT - 1 year ago

Roivant Provides Update on Graves' Disease Development Program

Aug 30, 2024, 8:00 AM EDT - 1 year ago

Top Stocks Near Their 200-Day SMA

CCL CUK SM

Aug 22, 2024, 1:00 AM EDT - 1 year ago

Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses

Jun 7, 2024, 6:26 PM EDT - 1 year ago

The 'Undercovered' Dozen From June 1-6

ALNY CLOV CRSP ENVX GAM HAL LPA

Jun 2, 2024, 7:27 AM EDT - 1 year ago

Roivant Sciences: Executing On Huge Buyback Program With More To Come

May 30, 2024, 12:23 PM EDT - 1 year ago

Roivant Sciences Ltd. (ROIV) Q4 2023 Earnings Call Transcript

May 30, 2024, 7:00 AM EDT - 1 year ago

Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update

Digger75 Oct. 23 at 2:51 PM

$ROIV this is going much higher

0 · Reply

DocPharm Oct. 23 at 1:37 PM

$ROIV

0 · Reply

DocPharm Oct. 22 at 8:28 PM

$MRNA down she blows May have to pay a big chunk to $ABUS / $ROIV / Genevant soon, too

2 · Reply

MyBrokenBus Oct. 22 at 4:13 PM

$ROIV Again. Roivant cares not for surrounding market volatility.

0 · Reply

lakeswim951 Oct. 21 at 3:30 PM

$ROIV The price action here along with $ABUS and $IMVT has been amazing👌

0 · Reply

DocPharm Oct. 21 at 12:04 PM

$INTC 😎😎 still has much more to go IMO, but nearing a double for moi Trimming 10-20% and rotating into bios $ABUS $EDIT $ROIV barinthus/vaccitech

2 · Reply

DocPharm Oct. 20 at 2:05 PM

$ROIV keep on keepin on

1 · Reply

Alfalcon Oct. 19 at 12:29 AM

$ROIV

0 · Reply

bbbloo Oct. 17 at 12:23 AM

2 · Reply

MTGDW Oct. 16 at 3:57 PM

$ROIV anyone concerned by Venker’s constant selling?

3 · Reply

DocPharm Oct. 16 at 12:02 AM

$ABUS Scientific Advisory Board has had about 6 months; CEO has had about 9 months should be announcing an investor call to detail their corporate overhaul & mission going forward Likely will tie it to the AASLD call, but stranger things have happened XBI looking like it wants to test 125-130, which will help $ROIV at ATH today again, with a mixed prospectus on the wire

0 · Reply

DocPharm Oct. 15 at 7:02 PM

$ROIV $17

1 · Reply

MyBrokenBus Oct. 10 at 5:40 PM

$ROIV completely shrugging off the general market melee. Seems pretty tough at these levels

0 · Reply

DocPharm Oct. 10 at 2:26 PM

$ROIV MARKET CAP > > $MRNA Dancing with fire $ABUS

3 · Reply